Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Early Rheumatoid Arthritis  (1)
  • IgA-alpha-1-antitrypsin Complex  (1)
  • Interleukin-10  (1)
  • 1
    ISSN: 1434-9949
    Schlagwort(e): Early Rheumatoid Arthritis ; IgA-alpha-1-antitrypsin Complex ; Acute Phase Proteins
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Summary We followed the levels of serum IgA-alpha-1-antitrypsin complex (IgA-AT), C-reactive protein (CRP), alpha-1-acidglycoprotein (AGP), and alpha-1-antichymotrypsin (ACT) in twenty-seven early rheumatoid arthritis (RA) patients during the first three years of the disease duration. Fifteen patients were treated with methotrexate (MTX), twelve patients with NSAIDs only. The IgA-AT serum concentrations were significantly higher in RA patients as compared to the control group (0.72±0.39 U, vs. 0.27±0.15 U, p〈0.01). It decreased in almost all individuals (23 cases) during the observation. This decrease occurred in both MTX treated and untreated patients; however, it was statistically significant (p〈0.01) only in MTX treated patients. On average, the levels of ESR, CRP, AGP, and ACT were higher at the beginning of the disease as compared to healthy controls. After three years duration of the disease, a significant decrease in serum levels of all these markers of acute phase response was observed. At the onset of the disease, AGP and ACT reactivity coefficients were normal; after three years they dropped. We demonstrated an association between IgA-AT level and erythrocyte sedimentation rate. No relationships were shown between IgA-AT levels and APP serum concentrations and APP glycosylation patterns in RA patients treated with MTX. Since decrease in IgA-AT level does not correlate with decrease in APP, we can suppose that observed changes in IgA-AT concentration depend rather on direct action of MTX on the complex, than the changes in disease course. Besides gold salts, D-penicillamine, and sulphasalazine, methotrexate may also destroy covalent linkage between IgA and antitrypsin.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    ISSN: 1434-9949
    Schlagwort(e): Systemic Lupus Erythematosus ; Rheumatoid Arthritis ; Interleukin-10 ; Interleukin-6 ; Acute Phase Proteins
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Summary We sought to investigate the influence of interleukin-10 (IL10) and IL-6 on the acute phase proteins (APP) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). IL-10, IL-6, Creative protein (CRP), alpha-1-acid glycoprotein (AGP), and alpha1 antichymotrypsin (ACT) serum levels were determined in one hundred-eight patients (71 with SLE, 37 with RA). Quantification of the serum IL-10 level showed increased levels in SLE and RA patients as compared to healthy controls. Serum IL-6 level was found to be elevated in SLE and RA patients. A correlation between IL-10 and IL-6 serum level was found only in SLE. CRP and AGP serum levels were increased in RA as compared to controls, whereas in SLE only AGP was found elevated. A statistically significant correlation between IL-6 serum level and CRP, AGP and ACT was found only in RA. No correlation between IL-10 and serum level of CRP, AGP and ACT was established. Since IL-10 has a potent immunosuppressive activity, we expected it to be negatively correlated with APP levels. Surprisingly, IL-10 did not correlate with APP either in SLE or RA patients. However, the elevation of IL-10 serum levels in SLE and RA and the correlation between IL-10 and IL-6 in SLE may suggest that IL-10 may play a central role in inflammatory connective tissue diseases.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...